Wedbush Securities Inc. raised its holdings in Proteon Therapeutics Inc (NASDAQ:PRTO) by 76.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 104,000 shares of the biopharmaceutical company’s stock after acquiring an additional 45,000 shares during the period. Wedbush Securities Inc.’s holdings in Proteon Therapeutics were worth $43,000 as of its most recent filing with the Securities and Exchange Commission.
PRTO stock opened at $0.32 on Wednesday. The stock has a market capitalization of $5.50 million, a P/E ratio of -0.28 and a beta of 0.42. The business has a 50-day moving average of $0.38 and a 200-day moving average of $1.16. Proteon Therapeutics Inc has a fifty-two week low of $0.27 and a fifty-two week high of $3.94.
Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.21). As a group, sell-side analysts anticipate that Proteon Therapeutics Inc will post -0.59 earnings per share for the current fiscal year.
About Proteon Therapeutics
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.
Featured Story: Intrinsic Value
Want to see what other hedge funds are holding PRTO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteon Therapeutics Inc (NASDAQ:PRTO).
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.